Komori
CellSource (4880) · InitiativeFirst stated

Launch of Contract Synovial-Derived Stem Cell Processing Services

First written in FY2023. . Latest entry: FY2023.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Launch of a Regenerative Medicine CDMO and Contract Cell Manufacturing BusinessA theme 13 companies write about · 1 as a headwind · 20 as a tailwind

The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2023First statedAnnual report

    「March 2023: Launched the “contract processing service for synovium-derived stem cells.”」

    In addition to the existing contract processing services for blood-derived and adipose-derived stem cells, a new contract processing service for synovium-derived stem cells was launched.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for CellSource yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Launch of Contract Synovial-Derived Stem Cell Processing Services | CellSource Co.,Ltd. (4880) | Komori